Novel enzyme-linked aptamer-antibody sandwich assay and hybrid lateral flow strip for SARS-CoV-2 detection

Shih-Wei Wu,Ying-Ju Chen,Yu-Wen Chang,Cheng-Yang Huang,Biing-Hui Liu,Feng-Yih Yu
DOI: https://doi.org/10.1186/s12951-023-02191-9
IF: 10.2
2024-01-03
Journal of Nanobiotechnology
Abstract:Abstract We have successfully generated oligonucleotide aptamers (Apts) and monoclonal antibodies (mAbs) targeting the recombinant nucleocapsid (N) protein of SARS-CoV-2. Apts were obtained through seven rounds of systematic evolution of ligands by exponential enrichment (SELEX), while mAbs were derived from the 6F6E11 hybridoma cell line. Leveraging these Apts and mAbs, we have successfully devised two innovative and remarkably sensitive detection techniques for the rapid identification of SARS-CoV-2 N protein in nasopharyngeal samples: the enzyme-linked aptamer-antibody sandwich assay (ELAAA) and the hybrid lateral flow strip (hybrid-LFS). ELAAA exhibited an impressive detection limit of 0.1 ng/mL, while hybrid-LFS offered a detection range of 0.1 – 0.5 ng/mL. In the evaluation using ten nasopharyngeal samples spiked with known N protein concentrations, ELAAA demonstrated an average recovery rate of 92%. Additionally, during the assessment of five nasopharyngeal samples from infected individuals and ten samples from healthy volunteers, hybrid-LFS displayed excellent sensitivity and specificity. Our study introduces a novel and efficient on-site approach for SARS-CoV-2 detection in nasopharyngeal samples. The reliable hybrid Apt-mAb strategy not only advances virus diagnostic methods but also holds promise in combating the spread of related diseases.
biotechnology & applied microbiology,nanoscience & nanotechnology
What problem does this paper attempt to address?
The problem this paper attempts to address is the development of a novel, highly sensitive detection method for the rapid identification of SARS-CoV-2 nucleocapsid (N) protein in nasopharyngeal samples. Specifically, the authors successfully designed two innovative detection techniques by generating oligonucleotide aptamers (Apts) and monoclonal antibodies (mAbs): enzyme-linked aptamer-antibody assay (ELAAA) and hybrid lateral flow strip (hybrid-LFS). These methods aim to improve the sensitivity and specificity of SARS-CoV-2 detection, thereby more effectively preventing and controlling the spread of the virus. ### Background Emerging infectious diseases such as SARS, MERS, and SARS-CoV-2 (COVID-19) have rapidly appeared, posing significant threats to global public health. Due to increased global travel and trade, these infectious diseases spread quickly in previously unaffected regions and populations. Therefore, developing effective detection methods to halt the spread of diseases has become crucial. Currently, the main diagnostic tools for infectious diseases include molecular diagnostics (detecting viral RNA), serological tests (detecting immunoglobulins against viral antigens), and rapid on-site tests (detecting viral antigens). Among these, real-time reverse transcription polymerase chain reaction (RT-PCR) is widely accepted as the gold standard in clinical testing, but it has drawbacks such as a high rate of false-negative results and the need for specialized equipment and personnel, limiting its application in low- and middle-income countries. ### Objective This paper aims to use SARS-CoV-2 as a model to develop a novel, highly sensitive enzyme-linked aptamer-antibody assay (ELAAA) and hybrid lateral flow strip (hybrid-LFS) for detecting SARS-CoV-2 nucleocapsid protein in nasopharyngeal samples. These methods not only improve detection sensitivity and specificity but also offer simplicity and low cost, aiding in more effective management and control of the spread of infectious diseases. ### Methods 1. **Generation of Aptamers and Monoclonal Antibodies**: Aptamers against SARS-CoV-2 nucleocapsid protein were generated using the Systematic Evolution of Ligands by Exponential Enrichment (SELEX) method, and monoclonal antibodies were obtained from the 6F6E11 hybridoma cell line. 2. **Development of ELAAA**: Using the generated aptamers and monoclonal antibodies, an enzyme-linked aptamer-antibody assay was developed, which showed excellent performance with a detection limit of 0.1 ng/mL. 3. **Development of hybrid-LFS**: Aptamers were conjugated with ovalbumin and horseradish peroxidase (HRP) to prepare a hybrid lateral flow strip, which had a detection range of 0.1-0.5 ng/mL. 4. **Performance Evaluation**: The sensitivity and specificity of ELAAA and hybrid-LFS were evaluated using nasopharyngeal samples with known N protein concentrations and samples from infected individuals and healthy volunteers. ### Results - **ELAAA**: When evaluated with 10 nasopharyngeal samples of known N protein concentrations, the average recovery rate was 92%. - **hybrid-LFS**: When evaluated with nasopharyngeal samples from 5 infected individuals and 10 healthy volunteers, it showed excellent sensitivity and specificity. ### Conclusion The ELAAA and hybrid-LFS methods developed in this study provide new efficient means for on-site detection of SARS-CoV-2, not only enhancing the reliability of viral diagnostic methods but also showing great potential in addressing the spread of related diseases.